Alternating electric fields for the treatment of glioblastoma
Mené sur 315 patients atteints d'un glioblastome et ayant reçu une chimioradiothérapie (durée médiane de suivi : 38 mois), cet essai évalue, du point de vue de la survie sans progression et de la survie globale, l'intérêt d'un traitement d'entretien combinant champs électriques alternatifs et témozolomide
Glioblastoma is the most common malignant tumor of the central nervous system,1 and one of the most difficult cancers to treat. Standard therapy includes maximal surgical resection, high-dose external-beam radiation therapy, and regional or systemic chemotherapy. Still, 5-year survival rates are only 5%.1 Current therapies lack specificity, fail to address tumor heterogeneity, or are limited because of an inability to penetrate the blood-brain barrier. Because conventional strategies lack success, investigational approaches,2- 6 with varying degrees of supportive evidence, are often used. Historically, advances in this field have been separated by decades of failure. Life expectancy for patients with glioblastoma has changed little during the past decade, and median survival remains at less than 15 months.7
JAMA , éditorial, 2014